



**TAM DUC CARDIOLOGY HOSPITAL
JOINT STOCK COMPANY**

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 01.2026/NQ-ĐHCD

Ho Chi Minh City, April 24, 2026

RESOLUTION

2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;
- Pursuant to the Charter of Tam Duc Cardiology Hospital Joint Stock Company approved by the General Meeting of Shareholders on April 28, 2022;
- Pursuant to Resolution No. VII.11/NQ-HĐQT dated March 2, 2026, and Notice No. 08-26/CV-TĐ issued by the Chairman of the Board of Directors on March 3, 2026, and based on the list of shareholders entitled to attend and vote at the 2026 Annual General Meeting of Shareholders as of the record date of March 24, 2026, as provided by the Vietnam Securities Depository and Clearing Corporation;


On April 24, 2026, at 08:17a.m., at Tam Duc Cardiology Hospital, No. 4 Nguyen Luong Bang Street, Tan My Ward, Ho Chi Minh City, the 2026 Annual General Meeting of Shareholders was convened with 109/278 shareholders attending, representing 13,658,992 shares, equivalent to 87,83% of the Company's total outstanding shares (13,658,992 / 15,552,000 shares).

- Pursuant to the Vote Counting Record of the Vote Counting Committee of the 2026 General Meeting of Shareholders dated April 24, 2026;
- Pursuant to the Meeting Minutes of the 2026 Annual General Meeting of Shareholders of Tam Duc Cardiology Hospital Joint Stock Company dated April 24, 2026.

The meeting discussed and unanimously approved the Resolution with the following contents:

Article 1. APPROVAL OF THE 2025 PERFORMANCE REPORT AND 2025 AUDITED FINANCIAL STATEMENTS

Regarding professional activities: In 2025, medical examination activities *were equivalent to* 2024 (81,083/ 81,428). Inpatient treatment *increased by 5%* compared to 2024 (4,565/ 4,344). A total of 270 *surgical cases* were performed, *a decrease of 24% compared to* 2024 (270/355). Interventional cardiology *increased by 4%* compared to 2024 (1,755/1,689). Cardiac electrophysiology activities in 2025 *increased by 10%* compared to 2024 (507/461). Paraclinical services in 2025 *increased by 3%* compared to 2024 (1,014,560/ 984,869).



Regarding financial performance:

	2025 Plan	2025 Actual
Total revenue:	VND 750 billion	VND 846.1 billion
Profit before tax:	VND 92 billion	VND 108.2 billion
Profit after tax:	VND 84 billion	VND 95.7 billion

The financial results for 2025 exceeded the plan, with revenue increasing by 12.8%.

Profit before tax reached VND 108.2 billion, an increase of 17.7% compared to the 2025 plan.

The pre-tax profit/total revenue ratio for 2025 is 12.79% (compared to 12.1% in 2024).

Voting: 100% approval

Article 2. APPROVAL OF THE SUPERVISORY BOARD'S REPORT FOR 2025

Voting: 100% approval

Article 3. APPROVAL OF THE PROFIT DISTRIBUTION PLAN FOR 2025. THE DIVIDEND RATE FOR 2025 IS 33% AS APPROVED BY THE 2025 GENERAL MEETING OF SHAREHOLDERS ON APRIL 25, 2025

Criteria	Amount (VND)
1. Profit After Tax for 2025	95,735,394,301
2. Allocation to Funds (Resolution 01.2025/NQ-ĐHCD dated April 25, 2025)	6,946,474,195
2.1. Board of Directors' Operating Fund (3.6% of PAT)	3,446,474,195
2.2. Reward and Welfare Fund	3,500,000,000
3. Remaining Profit for Dividend Distribution (3=1-2)	88,788,920,106
4. Dividend Distribution - Projected 33% of par value	54,022,736,000
4.1. First interim dividend, August 2025: 10%	16,370,526,000
4.2. Second interim dividend, February 2026: 10%	16,370,526,000
4.3. Third dividend payment (after approval by the General Meeting): 13%	21,281,684,000
5. Remaining Profit for 2025 (5=3-4)	34,766,184,106

Voting: 100% approval

Article 4. APPROVAL OF THE PROPOSAL TO AUTHORIZE THE BOARD OF DIRECTORS TO SELECT AN AUDIT FIRM FOR THE 2026 FINANCIAL STATEMENTS

The General Meeting of Shareholders authorizes the Board of Directors to decide on the selection of an audit firm for the 2026 financial statements.

Voting: 100% approval

Article 5. APPROVAL OF THE 2026 BUSINESS PERFORMANCE PLAN

Regarding personnel: *After 20 years of stable operation and development, the leadership and professional team of Tam Duc have matured. However, it is necessary to continue recruiting and providing advanced training in key technical positions such as emergency resuscitation, anesthesia and resuscitation, surgery, interventional cardiology, and cardiac electrophysiology, while focusing on nurturing key staff and future leadership to ensure sustainable development in the next phase.*

Regarding expertise: *In 2026, medical examination, emergency care, and inpatient treatment are expected to increase by 5% compared to 2025. The company will continue to develop specialized techniques and maintain stable professional quality, with targets including 300 cardiac surgeries, 1,500 interventional cardiac catheterizations, and 500 cardiac electrophysiology cases.*

Regarding finance:

<i>Total revenue:</i>	<i>VND 780 billion</i>
<i>Profit before tax:</i>	<i>VND 95 billion</i>
<i>Profit after tax:</i>	<i>VND 86 billion</i>
<i>Dividends:</i>	<i>20% of par value</i>

Voting: 100% approval

Article 6. APPROVAL OF THE 2026 FUND ALLOCATION PLAN

Board of Directors' Operating Fund: 3.6% of profit after tax

Reward and Welfare Fund: VND 3.5 billion

Voting: 100% approval

Article 7. APPROVAL OF THE 2026 DIVIDEND PAYMENT PLAN

First interim dividend for 2026 at a rate of 5% of par value: September 2026

Second interim dividend for 2026 at a rate of 5% of par value: January 2027

Third interim dividend for 2026 at a rate of 10% of par value: After the 2027 General Meeting of Shareholders

Voting: 100% approval

Article 8. APPROVAL OF THE PLAN FOR ISSUANCE OF SHARES TO INCREASE CHARTER CAPITAL FOR 2026 AS ATTACHED TO THE PROPOSAL NO. 02/TTr-HĐQT DATED MARCH 30, 2026 OF THE BOARD OF DIRECTORS

Voting: 100% approval

Article 9. APPROVAL OF EMPLOYEE REWARDS ON THE OCCASION OF THE 20TH ANNIVERSARY OF TAM DUC CARDIOLOGY HOSPITAL (MARCH 8, 2006 –



**MARCH 8, 2026) AS ATTACHED TO PROPOSAL NO. 01-2026/TTr-HĐQT DATED
MARCH 30, 2026 OF THE BOARD OF DIRECTORS**

Voting: 100% approval

This Resolution was presented at the General Meeting and unanimously approved by the General Meeting of Shareholders at 10:10 a.m. on April 24, 2026.

CHAIRMAN OF THE BOARD OF DIRECTORS



DR. NGUYEN NGOC CHIEU



**TAM DUC CARDIOLOGY HOSPITAL
JOINT STOCK COMPANY**

No.: 01.2026/BB-DHĐCĐ

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Ho Chi Minh City, April 24, 2026

MINUTES 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

Today, from 8:17 AM to 10:10 AM, on April 24, 2026, at Tam Duc Cardiology Hospital – No. 4 Nguyen Luong Bang, Tan My Ward, Ho Chi Minh City, the Annual General Meeting of Shareholders of Tam Duc Cardiology Hospital Joint Stock Company for 2026 took place.

A. CONVENE THE GENERAL MEETING

I. LEGAL BASIS:

- Pursuant to the Enterprise Law No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020;
- The Company Charter of Tam Duc Cardiology Hospital Joint Stock Company approved by the General Meeting of Shareholders on April 28, 2022;
- Pursuant to Resolution No. VII.11/NQ-HĐQT dated March 2, 2026, according to Notice No. 08-26/CV-TD signed by the Chairman of the Board of Directors on March 3, 2026, based on the list of securities holders exercising voting rights at the 2026 Annual General Meeting of Shareholders on the final registration date of March 24, 2026, of the Vietnam Securities Depository and Clearing Corporation, who have the right to attend the Meeting.

II. LEGALITY AND VALIDITY OF THE MEETING:

The Shareholder Eligibility Verification Committee and the General Meeting of Shareholders include:

1. MSc. Phan Thi Thanh Nga, Chief Financial Officer, Head of the Committee
2. MD. (Specialist Level I) Le Thi Huyen Trang, Member of the Supervisory Board, Member
3. Ms. Tran Thi Thanh Nhan, Deputy Director of Administration and HR, Secretary

The Meeting heard MSc. Phan Thi Thanh Nga, Head of the Shareholder Eligibility Verification Committee, announce the Shareholder Eligibility Verification Record and the General Meeting of Shareholders:

- Total number of shareholders invited to attend the Meeting: 278 shareholders, representing 15,552,000 voting shares of the Company.
- Number of shareholders owning or authorized to attend present: 109 shareholders, representing 13,658,992 shares, accounting for 87,83% of the Company's voting shares.



- According to the provisions of the Enterprise Law No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and the Company Charter of Tam Duc Cardiology Hospital Joint Stock Company approved by the General Meeting of Shareholders on April 28, 2022, today's General Meeting of Shareholders meets the legal conditions (ratio > 65%) to proceed.

III. APPROVAL OF THE ORGANIZATIONAL PERSONNEL LIST FOR THE MEETING:

The Chairman of the Board of Directors introduced the Chairing Board, Vote Counting Committee, and Secretariat of this General Meeting of Shareholders for approval by the Meeting:

The Chairing Board includes:

1. Dr. Nguyen Ngoc Chieu, Chairman of the Board of Directors, Chairperson
2. MSc. Dr. Phan Kim Phuong, Member of the Board of Directors, Member
3. Dr. (Specialist Level II) Do Van Buu Dan, General Director, Member

Vote Counting Committee includes:

1. MSc. Phan Thi Thanh Nga, Chief Financial Officer, Head of the Committee
2. Dr. (Specialist Level I) Le Thi Huyen Trang, Member Supervisory Board, Member
3. Ms. Tran Thi Thanh Nhan, Deputy Director of Administration and HR, Member

Secretariat includes:

1. Ms. Nguyen Ngoc Nhu Anh, Deputy Director of Administration, in charge of Corporate Governance, Head of the Committee
2. Ms. Le Minh Tram, Deputy Head of Administration Department, Member

B. CONTENT OF THE MEETING

I. REPORT OF THE BOARD OF DIRECTORS:

Dr. Nguyen Ngoc Chieu, Chairman of the Board of Directors, on behalf of the Board of Directors, reports to the General Meeting on the operational results for 2025.

1. Regarding professional matters:

a. Professional plan:

In 2025, outpatient consultations, emergency services, and inpatient treatments increased by 5% compared to 2024. Cardiac surgeries must reach 400 cases, and interventional cardiology and electrophysiology must exceed 2,000 cases.

b. Hospital Quality Management:

The hospital quality inspection results for 2024 achieved a score of 4.37/5. It is anticipated that in Q2/2026, the Department of Health will conduct an inspection and evaluation of the hospital's quality.

c. Professional results:

In 2025, outpatient consultations *were equivalent to* 2024 (81,083/81,428). Inpatient treatments *increased by* 5% compared to 2024 (4,565/4,344). Surgical activities *performed* 270 cases, *a decrease of* 24% compared to 2024 (270/355). Interventional cardiology *increased by* 4% compared to 2024 (1,755/1,689). In electrophysiology, 2025

increased by 10% compared to 2024 (507/461). Paraclinical activities in 2025 increased by 3% compared to 2024 (1,014,560/984,869).

Intensive Care Unit and *Specialized Treatment Area* are designated for patients requiring high-demand care and treatment. In 2025, outpatient visits in the Specialized Treatment Area were equivalent to 2024 (21,836/21,677). Patients opting for treatment in the Specialized Treatment Area increased by 40% for new patients and 25% for returning patients. This result reflects patient satisfaction and contributes positively to financial performance.

2. Regarding financial matters:

a. Plan and results:

	<i>Plan 2025</i>	<i>Actual 2025</i>	<i>Compared to 2024</i>
Total Revenue:	VND 750 billion	VND 846.1 billion	increased by 7.7%
Profit Before Tax:	VND 92 billion	VND 108.2 billion	increased by 13.9%
Profit After Tax:	VND 84 billion	VND 95.7 billion	increased by 13.6%

The financial results for 2025 exceeded the plan, with revenue increasing by 12.8%.

Profit before tax reached VND 108.2 billion, an increase of 17.7% compared to the 2025 plan.

The ratio of profit before tax to total revenue for 2025 is 12.79% (2024 was 12.1%).

b. Dividends:

Dividends of Tam Duc from 2016-2025 ranged from 30%-33% (2021: 10% due to the impact of Covid-19).

II. CONTENT FOR VOTING APPROVAL BY THE GENERAL MEETING OF SHAREHOLDERS:

Dr. Nguyen Ngoc Chieu, Chairman of the Board of Directors, presents the Proposal for the General Meeting of Shareholders to approve the following 09 items:

1. Approval of the 2025 Operational Report and the Audited Financial Statements for Fiscal Year 2025:

Regarding Professional Activities: In 2025, medical examination activities were equivalent to 2024 (81,083/81,428). Inpatient treatment increased by 5% compared to 2024 (4,565/4,344). Surgical activities performed 270 cases, a decrease of 24% compared to 2024 (270/355). Interventional cardiology increased by 4% compared to 2024 (1,755/1,689). Regarding cardiac electrophysiology, in 2025 increased by 10% compared to 2024 (507/461). Paraclinical activities in 2025 increased by 3 % compared to 2024 (1,014,560/984,869).

Regarding Financials:

	<i>Plan 2025</i>	<i>Actual 2025</i>	<i>Compared to 2024</i>
Total Revenue:	VND 750 billion	VND 846.1 billion	increased by 7.7%
Profit Before Tax:	VND 92 billion	VND 108.2 billion	increased by 13.9%
Profit After Tax:	VND 84 billion	VND 95.7 billion	increased by 13.6%

The financial results for 2025 exceeded the plan, with revenue increasing by 12.8%.

Profit before tax reached VND 108.2 billion, an increase of 17.7% compared to the 2025 plan.

The ratio of profit before tax to total revenue for 2025 is 12.79% (2024 was 12.1%).

2. **Approval of the 2025 Report of the Supervisory Board.**
3. **Approval of the 2025 Profit Distribution Plan. The 2025 dividend payout is 33% as decided by the 2025 General Meeting of Shareholders on April 25, 2025:**

Indicator	Amount (VND)
1. Profit after Corporate Income Tax 2025	95,735,394,301
2. Allocation to funds (Resolution 01.2025/NQ-ĐHĐCĐ dated 25.04.2025)	6,946,474,195
2.1. Board of Directors' Operating Fund (3.6% of Net Profit After Tax)	3,446,474,195
2.2. Reward and Welfare Fund	3,500,000,000
3. Remaining Profit for Dividend Distribution (3=1-2)	88,788,920,106
4. Dividend Distribution - Projected at 33% of Par Value	54,022,736,000
4.1. First Advance, August 2025: 10%	16,370,526,000
4.2. Second Advance, February 2026: 10%	16,370,526,000
4.3. Third Payment (Post General Meeting Approval): 13%	21,281,684,000
5. Remaining Profit for 2025 (5=3-4)	34,766,184,106

4. **Approval of the proposal to authorize the Board of Directors to select the auditing firm for the Financial Statements for Fiscal Year 2026:**

The General Meeting of Shareholders authorizes the Board of Directors to decide on the selection of the auditing firm for the Financial Statements for Fiscal Year 2026.

5. **Approval of the Business Operation Plan for 2026:**

Regarding personnel: *After 20 years of stable operation and development, the leadership and professional team of Tam Duc have matured. However, it is necessary to continue recruiting and providing postgraduate training in key technical positions such as emergency resuscitation, anesthesiology, surgery, cardiac catheterization, and cardiac electrophysiology, while focusing on nurturing key personnel and future leadership to ensure sustainable development in the next phase.*

Regarding expertise: *In 2026, outpatient visits, emergency care, and inpatient treatment are expected to increase by 5% compared to 2025. The development of specialized techniques and the maintenance of stable professional quality are targeted, including 300 heart surgeries, 1,500 interventional cardiac catheterizations, and 500 cardiac electrophysiology cases.*

Regarding finance:

Total revenue: VND 780 billion
Profit before tax: VND 95 billion

Profit after tax: VND 86 billion

Dividend: 20% of par value

6. Approval of the 2026 Fund Allocation Plan:

Board of Directors' Operating Fund: 3.6% of Profit after tax

Reward and Welfare Fund: VND 3.5 billion

7. Approval of the 2026 Dividend Payment Plan:

First interim dividend payment for 2026 at a rate of 5% of par value: September 2026

Second interim dividend payment for 2026 at a rate of 5% of par value: January 2027

Third dividend payment for 2026 at a rate of 10% of par value: After the 2027 General Meeting of Shareholders

8. Approval of the plan to issue shares to increase charter capital in 2026 as attached to Proposal No. 02/TTr-HĐQT dated March 30, 2026, of the Board of Directors.

9. Approval of the employee reward on the occasion of the 20th anniversary of the establishment of Tam Duc Cardiology Hospital from March 8, 2006, to March 8, 2026, as attached to Proposal No. 01-2026/TTr-HĐQT dated March 30, 2026, of the Board of Directors.

III. REPORT OF THE SUPERVISORY BOARD:

The meeting heard Mr. Nguyen Duc Tuan, Head of the Supervisory Board, present the Supervisory Board's Report for 2025.

Financial performance results: Tam Duc exceeded the 2025 plan, with revenue surpassing the target by 11.4%, profit before tax exceeding by 17.7%, and profit after tax exceeding by 14%.

Remarks:

- Tam Duc has achieved positive financial results for 19 consecutive years, from 2007 to the present.
- Always preserve and develop the hospital's capital. Financial management in terms of documentation shall adhere to proper regulations and current accounting standards, with the financial status reviewed by the auditing company mid-year and audited at the end of the fiscal year, with an unqualified opinion on the financial statements for 2025.
- Professional data reflects growth in most specialties, particularly, the hospital quality management criteria, and the satisfaction indices of both inpatients and outpatients continue to improve positively and sustainably in 2025.

IV. DISCUSSION

Mr. Dang Quoc Tien:

I am currently working at MB Bank and have been a long-term shareholder of Tam Duc. I highly appreciate Tam Duc's development strategy, particularly the values of "Compassion" and "Virtue" reflected in its patient care services, with a strong patient-centered approach. The team of doctors and specialists at Tam Duc have been trained overseas in countries such as the UK and France. I also note that Tam Duc's financial statements have consistently been transparent over the years. Additionally, Tam Duc has implemented the charitable cardiac surgery program (MT3) very effectively.

Following the issuance of shares to increase charter capital, how will the Company utilize these funds to ensure efficiency?

Dr. Nguyen Ngoc Chieu:

Tam Duc's establishment is closely associated with the policy of socialization of healthcare services. There were three key approaches to hospital development: engaging highly qualified retired professionals, implementing talent attraction policies, and recruiting and providing professional training. At that time, Tam Duc trained approximately 100 doctors and nurses, establishing a core workforce for its development. Currently, the proportion of doctors with postgraduate qualifications at Tam Duc stands at 86%.

After the share issuance to increase charter capital, the Company has utilized the funds for its operations; any unused funds are deposited in banks. At present, financial income from bank deposits amounts to approximately VND 5–7 billion per year.

When investing in new medical equipment, Tam Duc carefully evaluates technical aspects and conducts cost-benefit analyses. The Company consistently adheres to three operating principles: technical excellence, humanity, and efficiency.

Mr. Nguyen Thanh Hieu:

I am very satisfied with Tam Duc's operating results and financial statements.

Why has the hospital capacity remained at 250 beds instead of expanding to 500 beds, especially when charter capital is expected to increase to over VND 300 billion? However, I note that the number of inpatients in 2025 has not been particularly high, so expansion should be carefully considered. If we were to operate 500 beds, it appears feasible at the current location without the need for expansion to another site.

Dr. Nguyen Ngoc Chieu:

Currently, Tam Duc operates with a capacity of 250 beds, and utilization has not yet reached full capacity. Expansion will be considered once the number of outpatient visits reaches approximately 500 patients per day.

The General Meeting had no additional comments.

V. VOTING RESULTS ON 09 ITEMS SUBMITTED TO THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS FOR APPROVAL:

The General Meeting conducted voting on 09 items presented by the Chairman of the Board of Directors for approval.

MsC. Phan Thi Thanh Nga, Head of the Vote Counting Committee, announced the results as follows:

1. Voting on the approval of 09 items of the General Meeting:

Total ballots issued:	109 ballots
Total ballots collected:	109 ballots
Valid ballots:	109 ballots
Invalid ballots:	0 ballots

VOTE COUNTING RESULTS:

No.	CONTENT	AGREE		DISAGREE		OTHER OPINIONS	
		No. of Shares	(%)	No. of Shares	(%)	No. of Shares	(%)

1	Approval of the 2025 Business Results Report	13,658,992	100%	-	0%	-	0%
2	Approval of the Supervisory Board's Report 2025	13,658,992	100%	-	0%	-	0%
3	Approval of the 2025 Profit Distribution Plan. The 2025 Dividend Payout is 33% as resolved by the 2025 General Meeting of Shareholders on April 25, 2025	13,658,992	100%	-	0%	-	0%
4	Approval of the Proposal to Authorize the Board of Directors to Select the Audit Firm for the 2026 Financial Statements	13,658,992	100%	-	0%	-	0%
5	Approval of the 2026 Business Operation Plan	13,658,992	100%	-	0%	-	0%
6	Approval of the 2026 Fund Allocation Plan	13,658,992	100%	-	0%	-	0%
7	Approval of the 2026 Dividend Payment Plan	13,658,992	100%	-	0%	-	0%
8	Approval of the Plan to Issue Shares to Increase Charter Capital in 2026	13,658,992	100%	-	0%	-	0%
9	Approval of the Reward Plan for Employees on the Occasion of the 20th Anniversary of Tam Duc Cardiology Hospital's Establishment March 8, 2006 - March 8, 2026	13,658,992	100%	-	0%	-	0%

Conclusion: 100% of the delegates voted unanimously to approve the 09 items submitted to the General Meeting.

The General Meeting had no other comments.

VI. CLOSING OF THE GENERAL MEETING


Dr. (Specialist Level II) Do Van Buu Dan, General Director, read the Meeting Minutes and the Resolution of the General Meeting of Shareholders. The 2026 General Meeting of Shareholders unanimously approved, with no other comments.

MSc.Dr.Nguyen Ngoc Chieu, Chairman of the Board of Directors, on behalf of the Chairing Board, declared the closing of the 2026 General Meeting of Shareholders at 10:10AM.

The General Meeting concluded successfully.

This document consists of 07 pages and was approved by the 2026 Annual General Meeting of Shareholders.

SECRETARIAT



NGUYEN NGOC NHU ANH

CHAIRPERSON
CHAIRMAN OF THE BOARD OF DIRECTORS



DR. NGUYEN NGOC CHIEU